# Harvard Atherosclerosis Reversibility Project (HARP)

> **NCT00000461** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)**

## Conditions studied

- Cardiovascular Diseases
- Coronary Disease
- Heart Diseases
- Myocardial Ischemia

## Interventions

- **DRUG:** pravastatin
- **DRUG:** niacin
- **DRUG:** cholestyramine
- **DRUG:** gemfibrozil
- **DRUG:** fatty acids, omega-3

## Key facts

- **NCT ID:** NCT00000461
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1986-12
- **Primary completion:** —
- **Final completion:** 1992-11
- **Target enrollment:** — (—)
- **Last updated:** 2016-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000461, "Harvard Atherosclerosis Reversibility Project (HARP)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00000461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*